Composition comprising n-acetyl-carnitine, citicoline, uridine monophosphate, n-accetyl cysteine and l-glutathione, and its use in treating pain
WO2026126077A1PCT designated stage Publication Date: 2026-06-18PHARMASUISSE LABORATORIES SPA
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- PHARMASUISSE LABORATORIES SPA
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
AI Technical Summary
Technical Problem
Current treatments for neuropathic, nociplastic, and mixed pain, such as those involving alpha-lipoic acid and vitamin D, are associated with significant side effects and limited efficacy, necessitating a safer and more effective therapeutic approach.
Method used
A composition comprising N-acetyl-carnitine, citicoline, uridine monophosphate, N-acetyl cysteine, and L-glutathione, which enhances anti-inflammatory and analgesic effects without the use of alpha-lipoic acid or vitamin D.
Benefits of technology
The composition effectively treats neuropathic, nociplastic, and mixed pain by boosting anti-inflammatory action and improving analgesic effects, while avoiding common side effects of other treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000013_0001_TABLE 
Figure IMGF000013_0002_TABLE 
Figure IMGF000015_0001_TABLE
Abstract
The invention relates to a composition for the treatment of neuropathic pain, also chronic, nociplastic, and mixed. In particular, the composition of the invention comprises an association of active ingredients, i.e. N-acetyl-carnitine, citicoline, uridine monophosphate, N-acetyl cysteine, and L-glutathione, which has proved to be particularly effective in boosting anti-inflammatory action and therefore improving analgesic action in cases of neuropathic pain, also chronic, nociplastic, and mixed.
Need to check novelty before this filing date? Find Prior Art